for Journals by Title or ISSN
for Articles by Keywords
help
Followed Journals
Journal you Follow: 0
 
Sign Up to follow journals, search in your chosen journals and, optionally, receive Email Alerts when new issues of your Followed Journals are published.
Already have an account? Sign In to see the journals you follow.
Journal Cover Consumer Drugs
  [0 followers]  Follow
    
   Full-text available via subscription Subscription journal
   ISSN (Print) 1530-1206
   Published by Informa plc Homepage  [9 journals]
  • International Headwinds Counter J&J's Consumer Growth
           Confidence
    • Abstract: "Some much weaker markets and some macroeconomic conditions, particularly in China and India" prompt J&J to adjusts its overall and...      Related Stories
      EU Marketing Approval In Sight For 11 Drugs After CHMP OK; Thumbs Down For Two
      Ombudsman Probes Whether Industry Can Influence EMA In Pre-Submission Meetings
      Recent And Upcoming FDA Advisory Committee Meetings 
      PubDate: Wed, 19 Jul 2017 17:02:32 GMT
       
  • C&D Oral Care Marketing Flows To Professionals Through WaterPik
    • Abstract: Church & Dwight acquires Water Pik Inc. for $1bn in a deal that will give the Arm & Hammer marketer...      Related Stories
      More Than CAR-T: Hematologic Oncology Pipeline Offers Rich Menu Of Possible Approvals
      Consumer Health Weekly Trademark Review July 11, 2017 Etude House Proof 10
      C&D Oral Care Marketing Flows To Professionals Through WaterPik 
      PubDate: Tue, 18 Jul 2017 22:29:53 GMT
       
  • Consumer Health Weekly Trademark Review July 11, 2017
    • Abstract: Compiled from the Official Gazette of the U.S. Patent and Trademark Office] for [Class 3 (Cosmetics and Cleaning Preps) and...      Related Stories
      More Than CAR-T: Hematologic Oncology Pipeline Offers Rich Menu Of Possible Approvals
      C&D Oral Care Marketing Flows To Professionals Through WaterPik 
      PubDate: Tue, 18 Jul 2017 14:00:36 GMT
       
  • FTC Review Of Colgate Optic White Claims Delays Class Action Complaint
    • Abstract: A Colgate Optic White whitening claims class action complaint is stayed pending an FTC decision on the claims, a federal...      Related Stories
      Irish Health Minister Speaks About EMA Relocation, Drug Pricing, and Boosting Biosimilars
      Spain And Portugal Team Up To Buy Medicines
      FTC Review Of Colgate Optic White Claims Delays Class Action Complaint 
      PubDate: Wed, 12 Jul 2017 15:53:57 GMT
       
  • Consumer Health Weekly Trademark Review July 4, 2017
    • Abstract: Compiled from the Official Gazette of the U.S. Patent and Trademark Office, trade mark registrations and filings for opposition for...      Related Stories
      User Fee Reauthorization: ?Pre-Conferenced? Bill Aims For Quick Passage
      FDA Expanding Opioid REMS To Immediate Release Formulations
      New Danish Fees Include Extra Payment For Firms With Over 500 Employees Per Site 
      PubDate: Tue, 11 Jul 2017 00:04:33 GMT
       
  • RB Says Petya Cyberattack Froze Shipments, Could Cost £100M
    • Abstract: Beiersdorf and Merck also were impacted by the June 27 malware attack that rocked the globe, but RB?s the only...      Related Stories
      Keeping Track: US FDA Approves Sickle Cell Therapy Endari; Array Submits Binimetinib Again
      FDA?s 21st Century Cures Plan Gives Patient-Focused Drug Development A Boost
      RB Says Petya Cyberattack Froze Shipments, Could Cost £100M 
      PubDate: Sun, 09 Jul 2017 22:43:54 GMT
       
  • Clock Ticks On Adding OTC Monograph Reform To FDA User Fees Bill
    • Abstract: With Congress leaving Washington for Independence Day week and much of August, few days remain to consider adding to each...      Related Stories
      EMA Brings Non-EU Regulators Into CHMP Meetings
      Pharma Execs Urge Post-Brexit Regulatory Deal, As EMA Focuses On Redistribution Of MHRA Work
      FDA?s NDA And BLA Approvals: Triptodur, Pantoprazole, Omeprazole 
      PubDate: Thu, 06 Jul 2017 14:42:40 GMT
       
  • Consumer Health Weekly Trademark Review June 27, 2017
    • Abstract: Compiled from the Official Gazette of the U.S. Patent and Trademark Office, Class 3 Cosmetics and Cleaning Preps) and Class...      Related Stories
      OTC Switch Interest Cooled By Study Costs To Update Safety Data
      Lobbying Pays Off As UK Ministers Speak Out On Post-Brexit Regulatory Collaboration
      Abuse-Deterrent Opioid Manufacturers Want FDA To Set Conversion Deadline 
      PubDate: Wed, 05 Jul 2017 22:40:38 GMT
       
  • OTC Switch Interest Cooled By Study Costs To Update Safety Data
    • Abstract: Firms often are hesitant to prepare Rx-to-OTC switch applications because safety and efficacy data for their products are over a...      Related Stories
      EMA Brings Non-EU Regulators Into CHMP Meetings
      Pharma Execs Urge Post-Brexit Regulatory Deal, As EMA Focuses On Redistribution Of MHRA Work
      FDA?s NDA And BLA Approvals: Triptodur, Pantoprazole, Omeprazole 
      PubDate: Wed, 05 Jul 2017 11:24:50 GMT
       
  • Consumer Health Weekly Trademark Review June 20, 2017
    • Abstract: Compiled from the Official Gazette of the U.S. Patent and Trademark Office, Class 3 (Cosmetics and Cleaning Preps) and Class...      Related Stories
      Keeping Track: US FDA Approves Sickle Cell Therapy Endari; Array Submits Binimetinib Again
      EMA Suspends Some Activities To Focus On Brexit Relocation
      Medicines For Ireland Lays Out Priorities For Boosting Access To Generics And Biosimilars 
      PubDate: Thu, 29 Jun 2017 14:00:05 GMT
       
  • Safecor Recalls Acetaminophen, Calcium Vitamin Following GMP Citations
    • Abstract: Safecor Health?s recalls, recently categorized as class II by FDA, began in July 2016, a month after FDA?s Office of...      Related Stories
      Australian Industry Rejects Planned Tendering System For Off-Patent Drugs
      Insider Trading: Ex-Ariad Staffers Charged With Using FDA Info On Iclusig
      Generic Industry Gets 267 Reasons From FDA To Pursue ANDA Development 
      PubDate: Tue, 27 Jun 2017 21:37:26 GMT
       
  • Perrigo Predicts Upturn On OTC Private Label Breadth, Depth And Bandwidth
    • Abstract: Perrigo counts on its OTC private label dominance to thwart new store brand entries and give it a leg-up in...      Related Stories
      Australian Industry Rejects Planned Tendering System For Off-Patent Drugs
      Insider Trading: Ex-Ariad Staffers Charged With Using FDA Info On Iclusig
      Generic Industry Gets 267 Reasons From FDA To Pursue ANDA Development 
      PubDate: Fri, 23 Jun 2017 15:25:06 GMT
       
  • Oral Contraceptive Switch Advocates Reject User Age As Approval Factor
    • Abstract: FDA could soon receive an NDA from non-profit research group Ibis Reproductive Health and HRA Pharma, for an oral contraceptive...      Related Stories
      FDA?s NDA And BLA Approvals: Cotempla XR-ODT, Baxdela, Mydayis
      Recent And Upcoming FDA Advisory Committee Meetings
      EU Postpones Decision On EMA’s New Home To November 
      PubDate: Thu, 22 Jun 2017 14:02:03 GMT
       
  • States Ease Access To Oral Contraceptives Despite Rx Requirement
    • Abstract: Changes range from allowing pharmacists to prescribe the drugs to requiring insurers to insurers to cover purchases of the products.      Related Stories
      FDA?s NDA And BLA Approvals: Cotempla XR-ODT, Baxdela, Mydayis
      Recent And Upcoming FDA Advisory Committee Meetings
      EU Postpones Decision On EMA’s New Home To November 
      PubDate: Thu, 22 Jun 2017 14:00:45 GMT
       
  • OTC Sleep Aid Sales Snooze As Consumers Wake Up To Alternatives
    • Abstract: Natural products cut into sales of OTC sleep aids as more consumers prefer naturals as non-addictive and not causing grogginess...      Related Stories
      FDA?s NDA And BLA Approvals: Cotempla XR-ODT, Baxdela, Mydayis
      Recent And Upcoming FDA Advisory Committee Meetings
      EU Postpones Decision On EMA’s New Home To November 
      PubDate: Wed, 21 Jun 2017 18:00:29 GMT
       
  • P&G Could Lean Toward OTC Brand Sales With Activist Investor
           Influence
    • Abstract: Analysts consider the potential for P&G splitting up or selling OTC or beauty care assets following CEO David Taylor?s recent...      Related Stories
      FDA?s NDA And BLA Approvals: Symjepi, Calcium Gluconate
      Yet Another Delay For Landmark EU Clinical Trial Rules – Now To 2019
      Five Years On: UK Reviews Transposition Of EU Pharmacovigilance Directive, Other Changes 
      PubDate: Fri, 16 Jun 2017 17:01:39 GMT
       
  • Consumer Health Weekly Trademark Review June 6, 2017
    • Abstract: Class 3 (Cosmetics and Cleaning Preps) and Class 5 (Pharmaceuticals) compiled from the Official Gazette of the U.S. Patent and...      Related Stories
      New Plain Language Labeling Rules Come Into Play For Non-Rx Drugs In Canada
      Off-Label Communications: Near-Term ‘Seismic Shift’ In FDA Oversight Unlikely
      PTAB Tosses Two More Humira Patents; Will Supreme Court Eliminate IPR Proceeding? 
      PubDate: Thu, 15 Jun 2017 03:45:16 GMT
       
  • Rx 'Reformulation' In Herbal Sleep Aid Gives FDA A
           Nightmare
    • Abstract: FDA inspects Belmora?s website and product labeling in March and issues a warning letter that firm’s Elavil OTC Sleep Aid...      Related Stories
      PhRMA Lists NAFTA Renegotiation Priorities For Better US Exports
      Clinical Trial Applications In Denmark Fail To Match 2015 High
      Hep C And Other High-Cost Drugs Behind 10% Rise In Canadian Medicines Spend 
      PubDate: Wed, 14 Jun 2017 21:30:15 GMT
       
  • New Plain Language Labeling Rules Come Into Play For Non-Rx Drugs In
           Canada
    • Abstract: Sponsors of non-prescription drugs in Canada have until June 2021 to comply with new labeling obligations aimed at making it...      Related Stories
      Dompé On A Roll After Securing A “Yes” Under The UK’s Early Access Scheme
      Consumer Health Weekly Trademark Review June 6, 2017
      Off-Label Communications: Near-Term ‘Seismic Shift’ In FDA Oversight Unlikely 
      PubDate: Wed, 14 Jun 2017 15:23:03 GMT
       
  • Perrigo’s Latest Woe: Empty Emergency Contraceptive Packages
           Recalled
    • Abstract: Perrigo is recalling is Option 2 (levonorgestrel 1.5 mg) emergency contraceptive in US and Canada because the tablet is missing...      Related Stories
      Stability Or Chaos? UK Election Result Increases The Uncertainty For Pharma
      FDA?s NDA And BLA Approvals: Gleolan, Norvir Powder, Fibryna
      Recent And Upcoming FDA Advisory Committee Meetings 
      PubDate: Thu, 08 Jun 2017 20:06:31 GMT
       
 
 
JournalTOCs
School of Mathematical and Computer Sciences
Heriot-Watt University
Edinburgh, EH14 4AS, UK
Email: journaltocs@hw.ac.uk
Tel: +00 44 (0)131 4513762
Fax: +00 44 (0)131 4513327
 
Home (Search)
Subjects A-Z
Publishers A-Z
Customise
APIs
Your IP address: 54.162.232.51
 
About JournalTOCs
API
Help
News (blog, publications)
JournalTOCs on Twitter   JournalTOCs on Facebook

JournalTOCs © 2009-2016